TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3300
+0.0450 (+3.50%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.2850
Open1.2800
Bid1.3000 x 1000
Ask1.6000 x 800
Day's Range1.2800 - 1.3300
52 Week Range1.1800 - 5.1500
Volume20,951
Avg. Volume84,017
Market Cap6.1M
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)-2.7980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
  • Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering
    PR Newswire

    Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 1,000,000 American depositary shares ("ADSs") at a purchase price of $1.25 per ADS in a registered direct offering.

  • MarketWatch

    Therapix shares fall as it moves forward with cannabinoid drug

    Shares of Therapix Biosciences fell 5% in morning trading after the Israeli drugmaker said it would continue to test its experimental cannabinoid-based therapy as an autism treatment. The study, in Israel, will evaluate the safety and efficacy of THX-210 compared to cannabidiol (CBD) oil. Therapix plans to first seek approval in Israel; a submission to the Food and Drug Administration is expected to follow after 2020, interim CEO Ascher Shmulewitz said in an email. GW Pharmaceuticals markets the only FDA-approved cannabis-based medication, a treatment for children with two rare forms of epilepsy. The regulator last week updated its guidance on CBD, saying that there is limited data about the safety of CBD and that the available data it does have points to "real risks that need to be considered before taking CBD for any reason." Therapix stock has fallen 53% year-to-date. The S&P 500 has gained 24% so far this year.

  • Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder
    PR Newswire

    Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today the progression of its RESPECTRUM product candidate into clinical stage. The company plans to initiate a randomized, double blind placebo controlled study to evaluate the efficacy, safety and tolerability of RESPECTRUM in treating patients with Autism Spectrum Disorder (ASD). The trial objective is to assess the efficacy and safety of RESPECTRUM versus cannabidiol (CBD)-rich oil by ASD severity measurements. Patient population is expected to include autistic subjects aged five to 35, and is based on the "entourage effect" phenomenon, hence the company expects improved efficacy, safety and tolerability over CBD alone.

  • Benzinga

    The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...

  • Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal
    PR Newswire

    Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

    TEL AVIV, Israel, Nov. 20, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it received a written Notice of Delisting from the Listing Qualifications Department of The Nasdaq Capital Market ("Nasdaq"). The Company intends to appeal this decision by requesting a hearing before a Nasdaq Hearings Panel to review Nasdaq's decision to delist the Company.

  • Benzinga

    Therapix Pursues Reverse Merger With CBD Wellness Company Heavenly Rx

    Cannabis-focused investment company SOL Global Investments Corp. (CSE: SOL) (OTC: SOLCF) said Tuesday that its portfolio company, Heavenly Rx, Ltd., has entered into a memorandum of understanding with Therapix Biosciences Ltd (NASDAQ: TRPX) to chase a business combination. Therapix Biosciences is a pharmaceutical company with a portfolio of technologies based on cannabinoid pharmaceuticals. Under the MOU, both companies will further discuss a final agreement for a business combination, which includes a reverse takeover of Therapix by Heavenly Rx.

  • CNW Group

    SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences

    TORONTO , Nov. 19, 2019 /CNW/ - SOL Global Investments Corp. ("SOL Global" or the "Company") (SOL.CN) (SOLCF) (9SB.F) announced today that its 40.7% owned portfolio company Heavenly  Rx, Ltd. ("Heavenly Rx") has entered into a memorandum of understanding ("MOU") with the US NASDAQ listed public company, Therapix Biosciences Ltd (TRPX), a speciality clinical-stage pharmaceutical company with a portfolio of technologies and assets based on cannabinoid pharmaceuticals, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination. Pursuant to the MOU, the parties will negotiate a definitive agreement for a business combination between Therapix and Heavenly Rx, constituting a reverse takeover of Therapix by Heavenly Rx.

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.
    PR Newswire

    Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

    TEL AVIV, Israel, Nov. 18, 2019 Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), announced today that it entered into a memorandum of understanding ("MOU") with Heavenly Rx, Ltd. ("Heavenly Rx"), an emerging consumer hemp CBD company, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination.

  • Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
    PR Newswire

    Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today topline results from its Phase IIa clinical study at Assuta Hashalom Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆ -9-tetrahydracannabinol, THC) and CannAmide™ (palmitoylethanolamide, PEA), positively affects symptoms in adult subjects with obstructive sleep apnea (OSA).

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
    PR Newswire

    Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, along with Destiny Biosciences Global Corp. ("Destiny"), announced today the mutual decision to discontinue negotiations on the previously announced proposed merger. On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. According to the Letter of Intent, the parties agreed to allow until October 31, 2019 to complete definitive agreements before abandoning the transaction.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210
    PR Newswire

    Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

    TEL AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA). THX-210 is intended for the treatment of epilepsy, as well as inflammatory conditions. The study consisted of in vitro tests which examined potential synergy between CBD and PEA.

  • Benzinga

    The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...

  • Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.
    PR Newswire

    Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

    TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. ("Destiny"). On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. If completed, the transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

  • Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement
    PR Newswire

    Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

    TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Nasdaq Stock Market has granted the Company an extension until November 18, 2019, to regain compliance with Nasdaq Listing Rule 5550(b)(1), which will permit the continued listing of Therapix's stock on the Nasdaq Stock Market. As previously reported on May 23, 2019, Therapix received a letter notifying the Company that the stockholders' equity reported in the Company's Annual Report on Form 20-F for the year ended December 31, 2018, was below the minimum stockholders' equity of $2,500,000 required for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq listing rule 5550(b)(1).

  • Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
    PR Newswire

    Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement

    This license is issued by Health Canada under the authority of the Natural Health Products Regulations. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of 1 tablet 3 times daily.

  • Benzinga

    Cannabis M&A: Therapix Biosciences, Destiny Biosciences Plan Stock-For-Stock Deal

    THERAPIX BIOSCI/S ADR (NASDAQ: TRPX ) said Tuesday that it has signed a letter of intent for a merger with the Canadian cannabis company Destiny Biosciences. The deal is a stock-for-stock transaction valuing ...

  • Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million
    PR Newswire

    Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million

    TEL AVIV, Israel, July 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the signing of a letter of intent (the "LOI") for a proposed merger with Destiny Biosciences Global Corp. ("Destiny"). The transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

  • Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data
    PR Newswire

    Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data

    TEL AVIV, Israel , July 5, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on ...

  • Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program
    PR Newswire

    Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, June 18, 2019 /PRNewswire/  - Therapix Biosciences Ltd. ("Therapix" or "the Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆-9-tetrahydracannabinol) and CannAmide™ (palmitoylethanolamide, or PEA), positively affects symptoms in adult subjects with obstructive sleep apnea (OSA). The study is being conducted under the leadership of Professor Yaron Dagan, head of the Sleep Medicine Institute at Assuta, and Principal Investigator, Dr. Lilach Kemer.

  • Therapix Biosciences Issues Shareholder Update Letter
    PR Newswire

    Therapix Biosciences Issues Shareholder Update Letter

    TEL AVIV, Israel, May 29, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today released a shareholder update letter from its Chairman and CEO, Dr. Ascher Shmulewitz. On Friday, May 24, 2019, the closing price of Therapix Biosciences' ADRs dropped 24% from the prior day's closing price. The drop followed our announcement that the Company received a notification from Nasdaq regarding non-compliance with Nasdaq's minimum stockholders' equity standard, and other challenging events, including our failed investment in the pain clinics in Tennessee, and the collapse of the planned acquisition of the Company by FSD Pharma Inc. in December 2018.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...

  • Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance
    PR Newswire

    Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance

    TEL AVIV, Israel , May 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing ...